Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 23

1.

Durability of Hepatitis B e Antigen Seroconversion in Chronic Hepatitis B Patients Treated with Entecavir or Tenofovir.

Fong TL, Tien A, Jo KJ, Chu D, Cheung E, Mena EA, Phan QQ, Yu AS, Mohammed W, Velasco A, LeDuc VH, Nguyen N, Han SB, Chang M, Bae HS, Cho YW, Tong MJ, Cooper SL.

Dig Dis Sci. 2015 Nov;60(11):3465-72. doi: 10.1007/s10620-015-3775-9. Epub 2015 Jul 3.

2.

Is it necessary to delay antiviral therapy for 3-6 months to anticipate HBeAg seroconversion in patients with HBeAg-positive chronic hepatitis B in endemic areas of HBV genotype C?

Song BC, Cho YK, Jwa H, Choi EK, Kim HU, Song HJ, Na SY, Boo SJ, Jeong SU.

Clin Mol Hepatol. 2014 Dec;20(4):355-60. doi: 10.3350/cmh.2014.20.4.355. Epub 2014 Dec 24. Erratum in: Clin Mol Hepatol. 2015 Mar;21(1):104.

3.

Management of chronic hepatitis B: Canadian Association for the Study of the Liver consensus guidelines.

Coffin CS, Fung SK, Ma MM; Canadian Association for the Study of the Liver.

Can J Gastroenterol. 2012 Dec;26(12):917-38.

4.

Prediction of early HBeAg seroconversion by decreased titers of HBeAg in the serum combined with increased grades of lobular inflammation in the liver.

Bae SK, Yatsuhashi H, Hashimoto S, Motoyoshi Y, Ozawa E, Nagaoka S, Abiru S, Komori A, Migita K, Nakamura M, Ito M, Miyakawa Y, Ishibashi H.

Med Sci Monit. 2012 Dec;18(12):CR698-705.

5.

Durability of viral response after off-treatment in HBeAg positive chronic hepatitis B.

Song MJ, Song DS, Kim HY, Yoo SH, Bae SH, Choi JY, Yoon SK, Paik YH, Lee JS, Lee HW, Kim HJ.

World J Gastroenterol. 2012 Nov 21;18(43):6277-83. doi: 10.3748/wjg.v18.i43.6277.

6.

Management and treatment of hepatitis B virus in patients with HIV infection: A practical guide for health care professionals.

Klein MB, Baril JG, Charron MA, Fortin C, Lalonde R, Matte MF, Poliquin M, Talbot A, Therrien R, Tremblay C, Trottier B, Tsarevsky I, Villeneuve JP.

Can J Infect Dis Med Microbiol. 2011 Fall;22(3):88-96.

7.

Mathematical models of e-antigen mediated immune tolerance and activation following prenatal HBV infection.

Ciupe SM, Hews S.

PLoS One. 2012;7(7):e39591. doi: 10.1371/journal.pone.0039591. Epub 2012 Jul 2.

8.

De novo combination therapy with lamivudine and adefovir dipivoxil in chronic hepatitis B patients.

Fan XH, Geng JZ, Wang LF, Zheng YY, Lu HY, Li J, Xu XY.

World J Gastroenterol. 2011 Nov 21;17(43):4804-9. doi: 10.3748/wjg.v17.i43.4804.

9.

Lamivudine plus adefovir is a good option for chronic hepatitis B patients with viral relapse after cessation of lamivudine treatment.

Wang Z, Wu XL, Zeng WZ, Xu H, Zhang Y, Qin JP, Jiang MD.

Virol J. 2011 Aug 4;8:388. doi: 10.1186/1743-422X-8-388.

10.

Predictive effect of serial serum alanine aminotransferase levels on spontaneous HBeAg seroconversion in chronic genotype B and C HBV-infected children.

Wu JF, Su YR, Chen CH, Chen HL, Ni YH, Hsu HY, Wang JL, Chang MH.

J Pediatr Gastroenterol Nutr. 2012 Jan;54(1):97-100. doi: 10.1097/MPG.0b013e31822a033e.

11.

New approaches in the management of chronic hepatitis B: role of tenofovir.

Reijnders JG, LA Janssen H.

Infect Drug Resist. 2009;2:13-26. Epub 2009 Apr 24.

12.

Chronic hepatitis B: a global health problem requiring coherent worldwide treatment strategies.

Lau G, Marcellin P, Peters M.

Hepatol Int. 2007 Jun;1(2):316-25. doi: 10.1007/s12072-007-9006-5. Epub 2007 Jun 6.

13.

Sustained response to peginterferon alfa-2a (40 kD) with or without lamivudine in Asian patients with HBeAg-positive and HBeAg-negative chronic hepatitis B.

Piratvisuth T, Lau G, Chao YC, Jin R, Chutaputti A, Zhang QB, Tanwandee T, Button P, Popescu M.

Hepatol Int. 2008 Mar;2(1):102-10. doi: 10.1007/s12072-007-9022-5. Epub 2008 Feb 5.

14.

Characteristics of treatment naïve chronic hepatitis B in Bangladesh: younger populations are more affected; HBeAg-negatives are more advanced.

Alam S, Ahmad N, Mustafa G, Alam K, Khan M.

Saudi J Gastroenterol. 2008 Jan;14(1):15-9. doi: 10.4103/1319-3767.37796.

15.

Economic benefits of hepatitis B vaccination at sexually transmitted disease clinics in the U.S.

Miriti MK, Billah K, Weinbaum C, Subiadur J, Zimmerman R, Murray P, Gunn R, Buffington J.

Public Health Rep. 2008 Jul-Aug;123(4):504-13.

16.

Hepatitis B virus e antigen loss during adefovir dipivoxil therapy is associated with enhanced virus-specific CD4+ T-cell reactivity.

Cooksley H, Chokshi S, Maayan Y, Wedemeyer H, Andreone P, Gilson R, Warnes T, Paganin S, Zoulim F, Frederick D, Neumann AU, Brosgart CL, Naoumov NV.

Antimicrob Agents Chemother. 2008 Jan;52(1):312-20. Epub 2007 Nov 5.

17.

Management of chronic hepatitis B: consensus guidelines.

Sherman M, Shafran S, Burak K, Doucette K, Wong W, Girgrah N, Yoshida E, Renner E, Wong P, Deschênes M.

Can J Gastroenterol. 2007 Jun;21 Suppl C:5C-24C.

18.

Hepatitis B virus: inactive carriers.

Sharma SK, Saini N, Chwla Y.

Virol J. 2005 Sep 28;2:82. Review.

19.

T cell subsets in chronic hepatitis B and the effect of prednisolone withdrawal and interferon alpha-2b.

Im EH, Lee BS, Sung JK, Lee SO, Lee KT, Lee SM, Kim SH, Seo KS, Kim JH, Kim SG, Kim NJ, Lee HY.

Korean J Intern Med. 1999 Jan;14(1):1-8.

20.

Chronic hepatitis in childhood: the spectrum of the disease.

Bortolotti F, Calzia R, Vegnente A, Cadrobbi P, Rugge M, Armigliato M, Marazzi MG, Iorio R, Crivellaro C, Piscopo R, et al.

Gut. 1988 May;29(5):659-64.

Supplemental Content

Support Center